Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

AI Briefing

• – Medicus Pharma announces Phase 2 study results with SkinJect, positive data suggests 73% clinical clearance in 200-μg arm, may allow patients to avoid immediate surgical intervention.
• – Babar K. Rao MD, FAAD, to provide clinical interpretation of data during business update webcast on March 26
• – Phase 2 study demonstrates clinical clearance in 73% of treated lesions